Suneel Mundle

Experienced Biopharmaceutical Professional

[Umang Swami, MD, MSCI, FASCO @umangtalking]

Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel https://t.co/aYH06Fb2WU @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10)

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Check out our poster on Genomic classifier for prognostication of Asian men with localised PCa at #ASCOGU22
Molecular subtypes between Asian and non-Asian in >80,000 pats
🔸Lower % of ERG+
🔸Higher % of basal
🔸Lower angiogenesis
@Decipher_VCYT @ravikanesvaran @Davicioni

[Simon C @scserendipity1]

@neerajaiims @ASCO @OncoAlert @PCF_Science @urotoday @CaPsurvivorship @MundleSuneel @MAWJNJ @AzadOncology @montypal @DrChoueiri @TiansterZhang @PGrivasMDPhD @Huntsman_GU Great work Neeraj. Important data in many ways. PSA is very important to our patients and hopefully this rapid and deep response provides reassurance to them and their families. And it allows us an easy way of potentially identifying patients for de-escalation and escalation..

[ASCO @ASCO]

🎉 Announcing the #GU22 Featured Voices! Follow along for expert insights & join the discussion ⬇️

@neerajaiims @crisbergerot @PauloBergerot @NazliDizman @pre_rad @kidneycan @CaPsurvivorship @ERPlimackMD @KidneyCancerDoc @DrKarineTawagi

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU22 @ASCO Abs#73: Deep and rapid PSA responses with apalutamide correlates with improved HR QoL, FACT-P Physical Wellbeing, pain and fatigue in men with advanced #prostatecancer in Titan and Spartan trials 👇Weblink: https://t.co/Wc6FT5TWOi @OncoAlert @PCF_Science @urotoday

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU22 @ASCO Abs#89: Prior use of docetaxel in pts with mCSPC #prostatecancer did not further improve clinical benefits of apalutamide + ADT in TITAN. Need a trial testing efficacy of docetaxel when added to ADT+NHT backbone. https://t.co/FZRVkgCdAB @OncoAlert @PCF_Science

[Suneel Mundle @MundleSuneel]

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN - ScienceDirect https://t.co/t0KWwAfMr1

[Axel S. Merseburger @amerseburger]

Excited to discuss recent GU developments #EMUC21 join us for lunch symposium #mHSPC topic with expert panel @Ecastromarcos @ZilliThomas @stefanofanti4 @Uroweb @myESMO @uroupdate @ESTRO_RT @montypal

[Arun Azad @AzadOncology]

Pleased to present analysis of rash in SPARTAN and TITAN studies @ #EMUC21. Apalutamide rash is:
🔹Seen in 1/4 pts, typically early
🔹Transient, responds to early steroids, antihistamines
🔹Not A/W Rx outcome

🌟Apalutamide remains a safe and effective Rx for #ProstateCancer🌟

[Paperbirds_Oncology @PaperbirdsO]

New article: The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature https://t.co/6eEUoNqzQ9 #prostatecancer #oncology

[Mark Wildgust (he/him) @MAWildgust]

Important paper by @neerajaiims @scserendipity1 @amerseburger and other authors showing you can improve OS and rPFS with no increase in fatigue and maintaining QOL. @JUrology

[Suneel Mundle @MundleSuneel]

All very pertinent questions

[David Olmos @Dolmos77]

@cdanicas @neerajaiims @OncoAlert @Ecastromarcos I admit I am amazed, It is clearly very good news for mCRPC pts. Looking forward to see the data. Any potential differences in HRR+ and HRR negative subgroups? Other combinations has shown rPFS but not OS, would this show OS? In BRCAmut open question: combination VS sequential

[Suneel Mundle @MundleSuneel]

@Dolmos77 @cdanicas @neerajaiims @OncoAlert @Ecastromarcos All pertinent questions

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in👉Top downloaded papers among all @ASCO journals: Number 1 is TITAN phase 3's final OS results with apalutamide in men with mCSPC #ProstateCancer published in @JCO_ASCO Remarkable data on OS, QOL, PSA responses 👇Weblink: https://t.co/wk9p7VQtWf @OncoAlert @urotoday

[Simon C @scserendipity1]

And I believe lower tox than Abi. Look at Lattitude. Mature data, broad categories. We need to get these drugs to patients and drop ADT for those who respond well. Docetaxel isn’t relevant for most patients/doctors. It should be but it isn’t. A wise man told me that…

[UroToday.com @urotoday]

Apalutamide (ERLEADA®) #AUA21 Oral Presentations demonstrate the importance of #PSA as a key efficacy indicator and show strong patient adherence rates. #ReadNow details and conference coverage on UroToday > https://t.co/z5bBzSsThL @AmerUrological @JanssenUS @UroDrBen

[Stacy Loeb, MD @LoebStacy]

Join us for the #aua21 Highlights in Advanced #ProstateCancer session today 445pET with @SBoorjian @kibelas & Evan Yu - discussing the @AmerUrological guidelines, management of CRPC, germline & somatic testing https://t.co/lVTy7IOcmf

[Arun Azad @AzadOncology]

Highly impressive data. PSA remains an excellent (and cheap) early on-treatment biomarker for stratifying clinical outcomes in mHSPC and MO CRPC. Very important for both pts and physicians alike. @neerajaiims @MundleSuneel @scserendipity1 @amerseburger @DrMLChua

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Interesting data at #aua2021 PSA response with APA and Survival in Adv PCa from SPARTAN & TITAN & RWE. Scientific hypotheses for this correlation? Is PSA90 predictive or prognostic? @scserendipity1 @neerajaiims @amerseburger @MundleSuneel @AzadOncology https://t.co/RtfWZSfogI

[UroToday.com @urotoday]

PSA kinetics in patients with advanced #ProstateCancer treated With apalutamide: results from the #TITAN and #SPARTAN studies. Presentation by Kim Chi, MD @BCCancer. #AUA21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/4L7yFJKEpv @AmerUrological